Brainreader is thrilled to announce a successful funding round that raised $7,300,000, fueling the next phase of innovation for its revolutionary Neuroreader® technology. As the inventor of Neuroreader®, Brainreader has consistently been at the forefront of providing advanced medical image processing solutions. Neuroreader® is a state-of-the-art software designed for the automatic labeling, visualization, and volumetric quantification of brain structures from MRIs. This breakthrough tool offers clinicians immediate access to a detailed, self-explanatory volumetric report in less than 10 minutes, dramatically enhancing the speed and accuracy of assessing structural MRIs.
The raised capital will enable Brainreader to accelerate product development, expand clinical partnerships, and broaden its global market reach. Neuroreader® currently delivers clinically relevant quantitative data that plays a crucial role in the early detection of neurodegenerative diseases, providing critical support for physicians during diagnostic procedures. Its array of features—including thorough brain structure analysis, intuitive heat maps for both clinicians and patients, longitudinal reporting, and asymmetry index calculations—positions it as a fast, accurate, low-cost, and non-invasive diagnostic support tool. Utilizing 3D T1 images with 1mm slices as part of routine MRI scans, the technology truly provides transformational insights into brain health.
Further cementing its standing in the healthcare sector, Brainreader has achieved FDA clearance, CE marking, and HIPAA compliance, ensuring that Neuroreader® meets the highest quality and safety standards. This recent funding milestone is not only a validation of Brainreader’s pioneering approach but also a critical boost to continue empowering clinicians with cutting-edge tools aimed at improving patient outcomes worldwide.
